Xcelerate,
Inc. Now Trading Under Ticker Symbol XCRT
MAULDIN,
SC -- March 17, 2021 -- InvestorsHub NewsWire
-- Xcelerate, Inc.
(OTC:
XCRT), formerly known as
Union Dental Holdings Inc., announced
today
it
has been
issued a new ticker symbol
due to
the Company's recent name change. The new symbol is
"XCRT". "We believe this new ticker symbol is major step
forward in giving Xcelerate a clear identity,"
said Michael O'Shea, Xcelerate's CEO.
While
the
Company
is
currently pursuing
innovative
acquisitions at the patent/engineering level to join
with
early
stage medtech companies in
a controlled clinical care setting where developments will be
trialed, tested,
and
applied, no specific
agreements have yet been entered
into.
Xcelerate,
led by CEO Michael O'Shea, has a distinguished
advisory board including world renowned
neurosurgeon, Dr. Dilan
Ellegala and
Nobel
Prize Laureate Dr. Barry Marshall.
Dr.
Marshall
AC FRACP FRS FAA recently
joined
its
Advisory Board. In 2005 Dr. Marshall
and his longtime collaborator Dr. Robin Warren were awarded the
Nobel Prize in Physiology or Medicine for their discovery of the
bacterium Helicobacter
pylori (H.
pylori)
and its role in peptic ulcer disease. This discovery also
established the causative link between Helicobacter pylori
infection and stomach cancer. Currently Dr. Marshall serves as
Clinical Professor and Director of The Marshall Centre for
Infectious Diseases Research at University of Western Australia.
Additionally, Dr. Marshall has been involved with the establishment
of the Marshall Laboratory for Biomedical Engineering at Shenzhen
University.
Safe Harbor Statement
This press release may contain forward looking statements which are
based on current expectations, forecasts, and assumptions that
involve risks as well as uncertainties that could cause actual
outcomes and results to differ materially from those anticipated or
expected, including statements related to the amount and timing of
expected revenues as well as any payment of dividends on our common
and preferred stock, statements related to our financial
performance, expected income, distributions, and future growth for
upcoming quarterly and annual periods. Actual results and the
timing of certain events could differ materially from those
projected in or contemplated by the forward-looking statements due
to
a number of
factors among other matters, the Company may not be able to sustain
growth or achieve profitability based upon many factors including
but not limited to general stock market conditions. We have
incurred and will continue to incur significant expenses in our
expansion of our existing business and there is no assurance that
we will generate enough revenues to offset those costs in both the
near and long term. Additional expansion of our service offerings
may expose us to additional legal and regulatory costs and unknown
exposure(s) based upon the various geopolitical locations we will
be providing services in, the impact of which cannot be predicted
at this time.
Media Contact: Justin Baronoff
561-750-9800;
justin@transmediagroup.com